Navigation Links
Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
Date:3/17/2009

CHENGDU, China, March 17 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced it has adopted a new sales strategy for Azithromycin Dispersible Tablets.

On average it takes 6 months for the market of a new drug to mature. Tianyin launched Azithromycin Dispersible Tablets in October 2008 and to date, the Company has met its initial sales targets. This drug is widely recognized and used by a large population of patients in China with collective 2007 annual sales of approximately $350 million. As such, the Company is focusing its sales efforts on the "Cost Preference Strategy." Management expects that by the second half of calendar 2009, monthly revenues generated from the sale of Azithromycin Dispersible Tablets will increase approximately 367% to approximately $430,000 from the current level of $117,000 per month. If successful, this strategy will yield over $3.7 million in incremental revenues on an annual basis with further growth expected in the future.

With such a rapid expansion after the launch of the Azithromycin market penetration, Tianyin seized the opportunity to aggressively seek additional market share, while at the same time driving more sales to current distributors through its "Cost Preference Strategy." Tianyin currently applies the Cost Preference Strategy to its drugs with high market coverage such as Ginkgo Mihuan Oral Liquid and Arpu Shuangxin Granules. This strategy specifically focuses on reducing overall costs for the end customer while maintaining favorable margins through economies of scale in the production process.

Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, said, "We make prudent adjustments to our sales strategy based on the changes in the market to maximize the revenue and profit potenti
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
2. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
3. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
4. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
7. Tianyin Pharmaceutical Appoints Three New Independent Board Members
8. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
9. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
10. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
11. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Franklin, MA (PRWEB) September 17, 2014 ... pre-engineered version of its TerraPure tank . This ... tanks is molded from FDA-compliant linear polyethylene and available ... seven pre-installed fittings and ships in two weeks or ... same features and benefits found in Terracon’s existing TerraPure ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
(Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23
... , , , For quantitative, real-time PCR and two-step RT-PCR using sequence-specific , probes, , ... , Component, Included, ... , , , ... Yes, 2x premixed solution*, , ...
... , , , , For ... , , , , , , ... all reverse transcription with any amount of RNA from 50 ng to 2 ... higher sensitivity and , superior performance even with low copy numbers ...
... , , , , , ... of 139 human cancer-related genes for functional genomics research using , ... , , , , , , ... cancer researchers (see table below for a list of genes). Every siRNA ...
Cached Biology Technology:Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:9/17/2014)... plastic shopping bags and their environmental impact recently scored ... first statewide ban on the bags, and Governor Jerry ... bag industry is not yielding without a fight, according ... , the weekly newsmagazine of the American Chemical Society. ... that the anti-bag campaign logged its first small victory ...
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... Researchers at UTSouthwestern Medical Center have found that the ... called apoE3, helps repair the lining of blood vessels. ... the benefit of this repair, putting them at higher ... have identified one mechanism by which apoE3 promotes a ... is detrimental," said Dr. Philip Shaul , Professor ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... German . , Research has not proven that the ... off using contraceptive pills because this has been listed ... be narrowing their contraceptive choices without good reason, according ... Health Care (IQWiG). Different forms of contraception have other ...
... around 12 months of age, their brains actually begin ... by the time they start talking, babies actually already ... infants can be a challenging endeavor, researchers have begun ... what infants learn, according to a new report by ...
... Georgetown University Medical Center have discovered a novel way ... the world,s largest-selling breast cancer prevention and treatment drug. ... identify tamoxifen users who are no longer benefiting from ... sooner. , In the November 1 issue of the ...
Cached Biology News:Research shows that the pill does not deserve its reputation for causing weight gain 2Baby talk: The roots of the early vocabulary in infants' learning from speech 2Baby talk: The roots of the early vocabulary in infants' learning from speech 3'New' estrogen receptor found to be key player in tamoxifen resistance 2'New' estrogen receptor found to be key player in tamoxifen resistance 3
Request Info...
Limit of detection: <5 pg/ml...
Request Info...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
Biology Products: